Exciting times though Balance
Printable View
Pick up some at 50c. To see if there is any luck
The 4 top institutional shareholders (courtesy of the underwritten stock) have 31% of PEB - 116m shares.
They will keep throwing money to boost the sp of their shareholdings imo as it is a basic game now of spending another million dollar to boost the performance of the 116m shares they already own, are are stuck with.
Stuck with because no other institutions are showing they are interested.
It's probably accurate to say that there is progress, but there is a long way to go as the urologists on mass still need to be convinced that the cxbladder suite is good enough to replace what is there already. There is no guarantee here. However, there is probably a little renewed confidence to start building exposure again to PEB. A May announcement for 2H2016 could reveal a bit more. There needs to be some progress made on the Kaiser and CMS front.
Cautiously optimistic.
While it's great to see some positive news coming out, haven't we had this before? Approval from a large group, meaning access to millions of customers, only to find out it was just the first hurdle of many and now they will want to see a user program etc. Meaning actual sales are no closer, they're just theoretically possible now? Buyer beware? Or is this different, I haven't looked into it in detail. Still hope it pans out for them anyway and it's certainly not bad news in the mean time.
Exactly.
Remember this announcement in October 2013? "The agreement provides FedMed's contracted insurance carriers, third party
administrators, health and welfare funds, and self-insured health plans with
access to Cxbladder. More than 40 million Americans have access to FedMed's
National Provider Network of over 550,000 physicians, 4,000 hospitals and
60,000 ancillary care providers nationwide."
Well, history repeats itself and there are punters who jumped in on the latest announcement.
Some 8.8 million vets - heaps of potential customers there
Courtesy of Crackity :
A promising announcement but the jury is definitely still out on the merits of PEB as an investment. Quote below from Jan 2016 report - investors may note their a quite a few competing products and many are further down the track with approvals and have industry linkages.
Policy:
Initial diagnosis
The following urinary bladder tumor markers meet Blue Cross and Blue Shield of Alabama’s medical criteria for coverage as an adjunct in the diagnosis of bladder cancer only in conjunction with current standard diagnostic procedures (urine cytology or cystoscopy, with or without biopsy):
• BTA-STAT*, BTA-TRAK*;
• NMP22*, NMP22 BLADDER CHEK*;
• UROVYSION*;
The following urinary bladder tumor marker does not meet Blue Cross and Blue Shield of Alabama’s medical criteria for coverage and is considered investigational in the diagnosis of bladder cancer:
• IMMUNOCYT
Bladder cancer monitoring
The following urinary bladder cancer tumor markers meet Blue Cross and Blue Shield of Alabama’s medical criteria for coverage as an adjunct in the monitoring of bladder cancer only in conjunction with current standard diagnostic procedures (urine cytology or cystoscopy, with or without biopsy):
• BTA-STAT*, BTA-TRAK*;
• IMMUNOCYT*;
• NMP22*, NMP22 BLADDER CHEK*;
• UROVYSION*;
The use of all other bladder cancer tumor markers (including but not limited to, CertNDx, Cxbladder) do not meet Blue Cross and Blue Shield of Alabama’s medical criteria for coverage and is considered investigational in the diagnosis, monitoring, or screening for bladder cancer.